Amgen Inc.

ticker: AMGN step: 01 generated: 2026-05-12 source: quick-research

Amgen Inc. (AMGN) — Business Overview

Business Description

Amgen is one of the world's largest biopharmaceutical companies, with a portfolio of 14 products generating $1B+ in annual sales. After the $28B Horizon Therapeutics acquisition (closed October 2023), Amgen expanded its rare disease franchise (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS). The most important asset in the pipeline is MariTide — an obesity drug positioned for monthly/quarterly dosing vs. weekly GLP-1 leaders Wegovy + Zepbound, with Phase 3 readouts expected in 2027. CEO Robert Bradway has been at the helm since 2012.

Revenue Model

• Biologics (primarily injectable, ~85% of revenue): Anti-PCSK9 (Repatha), bone (Prolia, XGEVA, EVENITY), inflammation (Otezla, Enbrel), oncology/hematology (BLINCYTO, KYPROLIS, Vectibix, IMDELLTRA), rare diseases (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS)
• Biosimilars (~10%): Mvasi, Kanjinti, Amgevita, Wezlana, Riabni (oncology + immunology biosimilars to other companies' originators)
• Other/Royalties (~5%): Royalties from licensing partnerships

Products & Services

Cardiovascular / Metabolic (Growth Drivers)

• Repatha (PCSK9): $876M Q1 2026 (+34% YoY) — fastest growing product; primary prevention indication expanding
• MariTide (obesity, Phase 3): Long-acting GIPR antagonist + GLP-1 agonist; monthly or quarterly dosing potential

Bone Health (Declining post-LOE)

• Prolia (denosumab, osteoporosis): -28% in 2026 — biosimilar entry
• XGEVA (denosumab, oncology): -39% in 2026 — biosimilar entry
• EVENITY: Anabolic for severe osteoporosis — growing 30%+

Inflammation / Immunology

• Enbrel (etanercept): Older TNF; Medicare price negotiations effective 2026
• Otezla (apremilast): Psoriasis/PsA — facing European generic Jan 2026
• TEZSPIRE: Asthma (anti-TSLP) — record growth +30%+

Oncology / Rare Disease

• TEPEZZA (Horizon): Thyroid eye disease — $1.9B FY25
• KRYSTEXXA (Horizon): Refractory gout — $1.2B FY25
• UPLIZNA: NMOSD
• TAVNEOS: ANCA-associated vasculitis
• BLINCYTO, KYPROLIS, Vectibix: Hematology/oncology
• IMDELLTRA (tarlatamab): BiTE small cell lung cancer

MariTide Phase 3 Program

• MARITIME-1 + MARITIME-2: Chronic weight management, 72-week monthly dosing
• MARITIME-CV: Cardiovascular outcomes
• MARITIME-HF: Heart failure + CV risk
• Six global Phase 3 studies; data 2027

Customer Base & Go-to-Market

• Patients: Millions globally with cardiovascular, autoimmune, oncology, rare disease conditions
• Specialists + Hospitals: Cardiologists, rheumatologists, endocrinologists, ophthalmologists, oncologists, geneticists
• Payers: US PBMs/insurers, ex-US single-payer systems
• Channel: Direct specialty + biotech sales force
• Geographic mix: ~75% US, ~25% International

Competitive Position

Amgen has multiple top-3 positions in major therapy areas: #1 in PCSK9 (Repatha vs Praluent), #1 in cardiovascular cholesterol biologics, leading bone health franchise (despite biosimilar pressure), strong oncology biologic franchise. MariTide's monthly dosing positioning is critical differentiation vs. Wegovy/Zepbound weekly injections. Competitors: Lilly (Mounjaro/Zepbound + cardiometabolic), Novo Nordisk (Wegovy/Ozempic), AbbVie (immunology), Roche/Sanofi (multiple), Vertex (cardio + rare).

Key Facts

• Founded: 1980 (Applied Molecular Genetics) in Thousand Oaks, CA
• Headquarters: Thousand Oaks, CA
• Employees: ~25,000
• Exchange: NASDAQ
• Sector / Industry: Health Care / Biotechnology
• Market Cap: ~$165B (May 2026)
• CEO: Robert A. Bradway (since 2012)
• Dividend: $9.96 annual ($2.49 quarterly)
• 13+ consecutive years of dividend growth
• 14 products generating $1B+ each

ticker: AMGN step: 12 generated: 2026-05-12 source: quick-research

Amgen Inc. (AMGN) — Investment Catalysts & Risks

Bull Case Drivers

1. MariTide — monthly/quarterly obesity dosing differentiation — MariTide's potential edge over Novo Wegovy + Lilly Zepbound (weekly injections) is its monthly or quarterly dosing capability. Phase 2 maintenance data showed sustained weight loss with lower doses taken monthly/quarterly. Six Phase 3 studies underway (MARITIME-1, -2, -CV, -HF). Data 2027. Peak sales bull case: $10B+. If approved with monthly dosing, MariTide could capture 20-30%+ of GLP-1-naive patients who reject weekly injections.

2. Six growth drivers +24% YoY offsetting LOE drag — Repatha (+34%, Q1 sales $876M record), EVENITY, TEZSPIRE, TEPEZZA, KRYSTEXXA, BLINCYTO collectively delivered $5.6B in Q1 2026 (+24% YoY). Repatha primary prevention indication could expand the franchise to $6B+. This is a textbook biotech diversification — concentration risk is limited even though MariTide gets the headlines.

3. 3.3% dividend yield + 13-year growth track record — Dividend $9.96/share annual yielding 3.3%. Combined with ~13x forward P/E, this is a relatively cheap defensive biotech with multiple growth options. As Horizon debt deleverages and MariTide data approaches, the multiple has room for re-rating.

4. Horizon Therapeutics integration on track — TEPEZZA $1.9B FY25, KRYSTEXXA $1.2B FY25 — adding ~$3B+ in rare disease revenue from the $28B acquisition. UPLIZNA + TAVNEOS contributing. Integration appears smooth — provides a defensive diversification away from osteoporosis biosimilar risk.

Bear Case Risks

1. Biosimilar erosion accelerating — Prolia/XGEVA -32% combined — Q1 2026: Prolia + XGEVA combined fell 32% YoY. Full 2026 forecast: Prolia -28%, XGEVA -39%. Combined these represented ~$6B FY24 — meaningful contribution. Enbrel under Medicare price negotiations effective 2026. Otezla facing European generics Jan 2026. The LOE wave is the most aggressive in biotech.

2. MariTide Phase 3 timeline risk — "waiting year" — Bernstein downgraded Amgen labeling 2026 as a "waiting year" — full Phase 3 results not expected until 2027. Any safety signal (GI, muscle wasting), missed endpoints, or competitive disclosures (Lilly orforglipron, Novo amycretin) could push MariTide thesis further out.

3. FY26 revenue growth deceleration to 1-5% — Management guides FY26 revenue $37.1-38.5B (midpoint +3%) — sharp deceleration from +10% in 2025. Implies growth drivers + Horizon barely outpace LOE drag. Bears worry this is a 2-3 year "growth gap" before MariTide launches.

4. $60B debt + Horizon goodwill risk — Net debt/EBITDA ~2.7x is elevated for a biotech. Horizon goodwill significant — any TEPEZZA competitive disruption (Viridian VRDN-001, etc.) could trigger impairment. Capital allocation flexibility constrained for next 2-3 years.

Upcoming Events

• Q2 2026 earnings (July 2026) — Repatha trajectory; biosimilar erosion pace; MariTide Phase 3 enrollment milestones
• Q3 2026 earnings (October 2026) — Otezla EU generic actual impact; pipeline updates
• MariTide Phase 2 long-term extension data — Throughout 2026
• MariTide Phase 3 interim updates — Any glimpse of monthly/quarterly dosing data
• 2027 — MariTide Phase 3 topline data — The make-or-break event

Analyst Sentiment

Sell-side consensus is Hold / Moderate Buy — split views. Bulls (UBS, Seeking Alpha) see MariTide as game-changer, $450-550 by 2030. Bears (Bernstein Hold, "waiting year") focus on growth deceleration + biosimilar erosion. Average price targets in the $320-360 range vs. recent ~$310 trading levels (~3-15% upside). The stock is a binary 2027 MariTide bet — current consensus reflects modest upside without baking in either bull case.

Research Date

Generated: 2026-05-12